COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

NCORP Efforts Highlighted at ASCO Annual Meeting

Posted: June 18, 2019

As some 42,000 people made their way through the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago May 31-June 4, the efforts of the NCI Community Oncology Research Program (NCORP) were often evident in the awards, oral abstracts, presentations, and posters.

Awards went to several NCORP affiliated people, including:

Among the presentations were: “Clinical Controversies: Are Geriatric Syndromes in the Domain of the Oncologist?” by Supriya Gupta Mohile, MD, MS, FASCO, University of Rochester Medical Center NCORP with Miriam B. Rodin, MD, PhD, St. Louis University School of Medicine.

Numerous oral abstracts focused on NCORP studies, including:

Among the posters highlighting NCORP efforts were:

“Community and academic partnerships: Moving a new generation of clinical trials in NCI Community Oncology Research Program (NCORP) into community oncology practices (#2551).” Worta McCaskill-Stevens, MD, NCORP Director.

“Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG S0307 trial (#552).” Darya Kizub.

“SWOG S1417CD, Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (#TPS6652).” Veena Shankaran, MD.

“NRG-CC001, A phase III trial of hippocampal avoidance in addition to whole-brain radiotherapy plus memantine to preserve neurocognitive functions in patients with brain metastases (#2009).” Vinai Gondi, MD.

“NRG-CC003, A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer (#TPS8578).” Vinai Gondi, MD.

“The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications (#6604).” Joseph Unger, PhD.